Dr Ning Wang PhD, FHEA, MRes, MSc, BSc
Department of Oncology & Metabolism
The University of Sheffield
Beech Hill Road
Tel: +44 (0) 114 215 9216
Fax: +44 (0) 114 272 2457
email : email@example.com
I undertook my undergraduate (BSc) and postgraduate (MRes) training in biology at Ocean University of China. After moving to the UK in 2004, I studied the trend of Biotech-industry development at Loughborough University and gained my MSc in Management the following year. I then joined Professor Alison Gartland’s group in Sheffield and was awarded my PhD in 2010 after completing my PhD project in investigating the roles of purinergic signalling in osteoporosis. I was subsequently appointed as a Post-doctoral Research Associate in Dr Colby Eaton’s lab and developed the models used in the identification of dormant metastasis initiating tumour cells in a Cancer Research UK programme grant. I was then employed as a Senior Post-doctoral Research Associate in Professor Tim Skerry’s group within the Department of Oncology & Metabolism and worked on the Wellcome Trust sponsored programme in development of novel agents for the treatment of pancreatic cancer. I am currently an independent Research Fellow in the Academic Group of Bone Biology.
My research interests are focused on bone oncology and bone biology. My current autonomous research is to determine how exercise induced cellular changes affect cancer bone metastasis. I am also interested in characterizing metastasis initiating cells and investigating interactions between these cells and bone microenvironment, as continuous development of a Cancer Research UK sponsored research programme. In addition, investigating the role of purinergic signalling in other musculoskeletal diseases such as osteoporosis and osteoarthritis is also in my research interests.
My teaching interests are mainly supervising research projects for both postgraduates (PhD and MSc) and undergraduate (BMedSci and SSC). I also teach cancer and bone biology related lectures on the MSc in Human Nutrition, MSc in Molecular Medicine, and the CIMA MRes Musculoskeletal Ageing.
I regularly review research articles for a number of international journals such as Scientific Reports, PlosOne, Anti-Cancer Drugs, and Journal of Bone Oncology, as well as grant applications for external funding bodies.
- Determining the impact of mechanical loading induced bone remodelling on the initiation and progression of prostate cancer skeletal metastasis (Prostate Cancer UK Research Innovation Award)
- Determining the impact of exercise on the initiation of breast cancer skeletal metastasis using pre-clinical models (Weston Park Cancer Charity Large Grant)
- Defining the role of P2X7 receptor in the prostate cancer metastasizing into the skeleton (The Royal Society International Exchange Scheme)
- N Wang, Agrawal A, Jørgensen NRA Gartland. P2X7 receptor regulates osteoclast function and bone loss in a mouse model of osteoporosis. Sci Rep. 2018 Feb 22;8(1):3507. doi: 10.1038/s41598-018-21574-9.
- N Wang, K Reeves, H Brown, A Fowles, F Docherty, P Ottewell, I Holen, PI Croucher, CL Eaton. The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. J Eep Clin Canc Res 2015, Oct 20;34:124. doi: 10.1186/s13046-015-0240-8.
- N Wang, F Docherty, H Brown, K Reeves, A Fowles, M Lawson, P Ottewell, I Holen, PI Croucher, CL Eaton. Mitotic quiescence, but not ‘stemness’, marks the phenotype of bone metastasis initiating cells in prostate cancer. FASEB J. 2015 Aug. 29(8):3141-50. doi: 10.1096/fj.14-266379.
- N Wang, F Docherty, H Brown, K Reeves,A Fowles, P Ottewell, I Holen, PI Croucher, CL Eaton. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis –evidence from in vivo models. J Bone Miner Res 2014 Dec;29(12):2688-96. doi: 10.1002/jbmr.2300.
- N Wang, B Robaye, F Gossiel, JM Boeynaems, TM Skerry, A Gartland. The P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development. FASEB J. 2014, 28(5):2249-59. doi: 10.1096/fj.13-243626.
- N Wang, RMH Rumney, L Yang, B Robaye, JM Boeynaems, TM Skerry, A Gartland. The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading. J Bone Miner Res. 2013, 28(6):1446-56. doi: 10.1002/jbmr.1877.
- N Wang, B Robaye, A Agrawal, G Reilly, JM Boeynaems, A Gartland. Reduced bone turnover in mice lacking the P2Y13 receptor. Mol. Endocrinol. 2012, 26(1):142-152. doi: 10.1210/me.2011-1083.
For a full list of publications click here